No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
Avacopan |
Avacopan |
D11093 |
1件: C5AR1 |
3件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
4件: 43, 44, 222, 223 |
2 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
3 |
Belimumab |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
8件: 11, 43, 44, 46, 49, 51, 53, 222 |
4 |
Belimumab 10 mg/kg |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 43, 46, 49 |
5 |
Blisibimod |
Blisibimod |
D10311 |
- |
- |
5件: 43, 44, 49, 63, 66 |
6 |
Ccx168 |
- |
- |
- |
- |
6件: 43, 44, 66, 109, 222, 223 |
7 |
Cellcept (mycophenolate mofetil) |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 42, 43 |
8 |
Chimeric monoclonal antibody, igg4 subtype |
- |
- |
- |
- |
2件: 43, 44 |
9 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
10 |
Corticosteroid and azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
4件: 42, 43, 44, 45 |
11 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
12 |
Cyclophosphamide, azathioprine,prednisone,methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 42, 43, 45 |
13 |
Freeze-dried sulfonated human normal immunoglobulin (ggs) |
Immune globulin human |
- |
- |
- |
3件: 14, 43, 45 |
14 |
Galen® tablet |
- |
- |
- |
- |
2件: 43, 44 |
15 |
Glucocorticoid (gc) |
- |
- |
- |
- |
2件: 43, 44 |
16 |
Glucocorticoids |
- |
- |
- |
- |
6件: 40, 41, 43, 44, 60, 62 |
17 |
Glucocorticoids (gc) |
- |
- |
- |
- |
2件: 43, 44 |
18 |
Glucocorticoids - reduced dose |
- |
- |
- |
- |
2件: 43, 44 |
19 |
Glucocorticoids - standard dose |
- |
- |
- |
- |
2件: 43, 44 |
20 |
Human normal immunoglobulin |
Immune globulin human |
- |
- |
- |
8件: 11, 13, 14, 43, 45, 50, 63, 65 |
21 |
Ifx-1 |
- |
- |
- |
- |
3件: 43, 44, 269 |
22 |
Infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
22件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
23 |
Intravenous immunoglobulins (human immunoglobulins g) |
- |
- |
- |
- |
1件: 43 |
24 |
Intravenous methyl prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 43 |
25 |
Mabthera® |
- |
- |
- |
- |
6件: 13, 35, 43, 44, 46, 93 |
26 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
27 |
Methyl prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 43, 49, 96 |
28 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
29 |
Methylprednisolone (or other glucocorticoid) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 43 |
30 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
31 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
32 |
Mycophenolate mofetil,methotrexate |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
3件: 42, 43, 45 |
33 |
Naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
34 |
Naltrexone hydrochloride |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
7件: 10, 40, 41, 42, 43, 44, 45 |
35 |
Pednisone |
- |
- |
- |
- |
2件: 43, 44 |
36 |
Placebo (physiological saline) |
- |
- |
- |
- |
2件: 43, 45 |
37 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
38 |
Prednison acis® 20 mg |
- |
- |
- |
- |
2件: 43, 44 |
39 |
Prednison acis® 5 mg |
- |
- |
- |
- |
2件: 43, 44 |
40 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
41 |
Prednisone (and methylprednisolone) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 43 |
42 |
Prednisone tablets, usp |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 41, 43, 44 |
43 |
Prednisone, methylprednisolone,cyclophosphamides |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 42, 43, 45 |
44 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
45 |
Rituximab (arm a) |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
2件: 43, 44 |
46 |
Rituximab (arm b) |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
2件: 43, 44 |
47 |
Rixathon 500mg |
- |
- |
- |
- |
1件: 43 |
48 |
Ro0452294/v01 |
- |
- |
- |
- |
2件: 43, 44 |
49 |
Ro0452294/v02 |
- |
- |
- |
- |
3件: 35, 43, 44 |
50 |
Same |
Ademetionine |
D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
51 |
Tocilizumab |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |